Emyria has released its latest Company Update, highlighting our:

• Clinical Focus
• Investment Highlights,
• Vision
• Advanced cannabinoid development
• Our Real World Data
• Clinical Program – Including Emyria’sUltra-Pure cannabinoid delivery platform
• Preclinical Pipeline
• Clinical opportunities for MDMA analogues
• Corporate Details & IP
• Leadership and Advisory team
• Patent portfolio
• Corporate structure

You can read the complete December 2022 Company Overview here